APA (7th ed.) Citation

TJ, J., HT, L., N, G., YJ, J., SB, C., UB, P., . . . YS, H. (2022). The High-Resolution Structure Reveals Remarkable Similarity in PD-1 Binding of Cemiplimab and Dostarlimab, the FDA-Approved Antibodies for Cancer Immunotherapy. Biomedicines, 10(12), . https://doi.org/10.3390/biomedicines10123154

Chicago Style (17th ed.) Citation

TJ, Jeong, Lee HT, Gu N, Jang YJ, Choi SB, Park UB, Lee SH, and Heo YS. "The High-Resolution Structure Reveals Remarkable Similarity in PD-1 Binding of Cemiplimab and Dostarlimab, the FDA-Approved Antibodies for Cancer Immunotherapy." Biomedicines 10, no. 12 (2022). https://doi.org/10.3390/biomedicines10123154.

MLA (9th ed.) Citation

TJ, Jeong, et al. "The High-Resolution Structure Reveals Remarkable Similarity in PD-1 Binding of Cemiplimab and Dostarlimab, the FDA-Approved Antibodies for Cancer Immunotherapy." Biomedicines, vol. 10, no. 12, 2022, https://doi.org/10.3390/biomedicines10123154.